Logo
Sale!
VLS Tirzepatide
VLS Tirzepatide - Image 2

VLS Tirzepatide

Original price was: £155.00.Current price is: £135.00.

Availability: 5 in stock

Category:

20MG Tirzepatide

20mg Means

8 weeks of 2.5mg dose

How it works?

VLS Tirzepatide works by mimicking the GLP-1 and GIP hormones that are naturally secreted by the intestine after a meal, which prompts insulin secretion.

VLS Tirzepatide also reduces appetite by slowing down the time it takes the stomach to empty and interacting with areas in the brain harboring GLP-1 receptors to signal satiety.

VLS Tirzepatide
for Weightloss
  •  FDA approved in 2023
  •  Up to 24.6% weight loss over 72 week trials
  •  Powerful apetite suppresant
  •  Regulates blood sugar
  •  Can help improve cardiovascular risk factors
  •  Improves lipid levels

Usage

Weeks 1 through 4: 2.5 mg subcutaneously once a week

Initial Dose Escalation Schedule

✔
Weeks 1 through 4: 2.5 mg subcutaneously once a week
Week 1 – 4

✔
Weeks 5 through 8: 5 mg subcutaneously once a week
Week 5 – 8

✔
Weeks 9 through 12: 7.5 mg subcutaneously once a week
Week 9 – 12

✔
Weeks 13 through 16: 10 mg subcutaneously once a week
Week 13 – 16

Maintenance Dose

✔
Week 17 and onward: 10 mg subcutaneously once a week
Week 17+

Dosing Considerations

⚠️
If dose escalation is not tolerated, consider delaying dose escalation for 4 weeks

⚠️
Do not increase dose if desired results are achieved at a lower dose, most people maintain at 5mg per week

Instructions

Step 1:

  1. Wash your hands with soap and water.
  2. Check the name and colored label of your pen, to make sure that it contains VLS Tirzepatide. This is especially important if you take more than 1 type of medicine.
  3. Pull off the pen cap.

Step 1 Illustration

Step 2:

  1. Check that the VLS Tirzepatide medicine in your pen is full, VLS Tirzepatide under very cold conditions can look cloudy, this will resolve at room temperature and does not effect the product.

Step 2 Illustration

Step 3:

  1. Take a new needle, and tear off the paper tab.
  2. Do not attach a new needle to your pen until you are ready to give your injection.

Step 2 Illustration

Step 4:

  1. Push the needle straight onto the pen. Turn until it is on tight.

Step 2 Illustration

Step 5:

  1. The needle is covered by 2 caps. You must remove both caps. If you forget to remove both caps, you will not inject any medicine.
  2. Pull off the outer needle cap. Do not throw it away.

Step 2 Illustration

Step 6:

  1. Pull off the inner needle cap and throw it away.

Step 2 Illustration

Step 7:

  1. Check the VLS Tirzepatide flow before the first injection with each new pen only.
  2. Turn the dose selector until the dose counter shows the flow check symbol ▪▪▰.

Step 2 Illustration

Step 8:

  1. Hold the pen with the needle pointing up. Press and hold in the dose button until the dose counter shows 0. The 0 must line up with the dose pointer. A drop of VLS Tirzepatide will appear at the needle tip.
  2. If no drop appears, repeat Step 7 above as shown in Figure G and Figure H up to 6 times.
  3. If there is still no drop, change the needle and repeat Step 7 as shown in Figure G and Figure H, 1 more time. Do not use the pen if a drop of VLS Tirzepatide still does not appear.

Step 1 Illustration

Step 9:

Select your dose
  1. Hold the pen with the needle pointing up. Press and hold in the dose button until the dose counter shows 0. The 0 must line up with the dose pointer. A drop of VLS Tirzepatide will appear at the needle tip.
  2. Turn the dose selector until the dose counter stops and shows your 2 mg dose. The dashed line in the dose counter (┇) will guide you to 2 mg.
  3. Always use the dose counter and the dose pointer to see that 2 mg has been selected. You will hear a “click” every time you turn the dose selector. Do not set the dose by counting the number of clicks you hear. Only doses of 2 mg can be selected with the dose selector.

Step 1 Illustration

Step 10:

To see how much VLS Tirzepatide is left in your pen, use the dose counter:
  1. Turn the dose selector until the dose counter stops.
  2. If it shows 1, at least 1 mg is left in your pen. If the dose counter stops before 1 mg, there is not enough VLS Tirzepatide left for a full dose of 1 mg.
  3. If there is not enough VLS Tirzepatide left in your pen for a full dose, do not use it. Use a new VLS Tirzepatide pen.

Step 1 Illustration

Step 11:

Inject your dose
  1. Choose your injection site and wipe the skin with an alcohol swab. Let the injection site dry before you inject your dose (See Figure K).

Step 1 Illustration

Step 12:

  1. Insert the needle into your skin as your healthcare provider has shown you.
  2. If it shows 1, at least 1 mg is left in your pen. If the dose counter stops before 1 mg, there is not enough VLS Tirzepatide left for a full dose of 1 mg.
  3. Make sure you can see the dose counter. Do not cover it with your fingers. This could stop the injection.

Step 1 Illustration

Step 13:

  1. Press and hold down the dose button until the dose counter shows 0.
  2. The 0 must line up with the dose pointer. You may then hear or feel a click.
  3. Continue pressing the dose button while keeping the needle in your skin.

Step 1 Illustration

Step 14:

  1. Count 6 seconds while keeping the dose button pressed.
  2. If the needle is removed earlier, you may see a stream of VLS Tirzepatide coming from the needle tip. If this happens, the full dose will not be delivered.

Step 1 Illustration

Step 15:

  1. Remove the needle from your skin. You can then release the dose button.
  2. If blood appears at the injection site, press lightly with a gauze pad or cotton ball.
  3. Do not rub the area.

Step 1 Illustration

Step 16:

After your injection
  1. Carefully remove the needle from the pen. Do not put the needle caps back on the needle to avoid needle sticks.

Step 1 Illustration

Step 17:

  1. Place the needle in a sharps disposal container right away to reduce the risk of needle sticks.

Step 1 Illustration

Step 18:

  1. Put the pen cap on your pen after each use to protect VLS Tirzepatide from light.

Step 1 Illustration

Step 19:

  1. If you do not have a sharps disposal container, follow a 1-handed needle recapping method. Carefully slip the needle into the outer needle cap. Dispose of the needle in a sharps disposal container as soon as possible.
  2. Never try to put the inner needle cap back on the needle. Always remove the needle from your pen.
  3. Always dispose of the needle after each injection.

Step 1 Illustration

Reviews

There are no reviews yet.

Be the first to review “VLS Tirzepatide”

Your email address will not be published. Required fields are marked *

FAQs

Q: What are the possible side effects of VLS Retatrutide?
Common Side Effects:
1. Gastrointestinal Issues:
  • ○ Nausea: A common side effect, especially when starting the medication. This tends to improve over time as the body adjusts.
  • ○ Vomiting: Some people may experience vomiting, particularly during the initial stages of treatment.
  • ○ Diarrhea or Constipation: These can occur, with some people experiencing one more than the other.
  • ○ Abdominal Pain: Stomach discomfort or pain is also reported by some users.
 
2. These gastrointestinal side effects tend to be temporary but can be bothersome for some people. Doctors often recommend starting with a lower dose and gradually increasing to help minimize these symptoms.
 
3. Decreased Appetite
  • ○ While this is a desired effect for many, some people may experience it too strongly, leading to reduced food intake and potential issues like fatigue or weakness.
 
Less Common but Serious Side Effects:
1. Thyroid Tumors (Including Medullary Thyroid Cancer):
  • ○ Potential Risk: Similar to other GLP-1 receptor agonists, retatrutide may carry a risk of thyroid tumors, including medullary thyroid cancer (MTC), and a possible increased risk of developing certain types of thyroid conditions.
  • ○ Caution for those with a Family History: It is especially not recommended for people with a family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2).
 
2. Pancreatitis (Inflammation of the Pancreas):
  • ○ Symptoms: Severe abdominal pain, nausea, and vomiting could indicate pancreatitis. If this happens, the drug should be discontinued immediately, and medical attention sought.
 
3. Kidney Problems:
  • ○ Dehydration Risk: If nausea, vomiting, or diarrhea are severe, dehydration could occur, which may lead to kidney problems. People with preexisting kidney conditions may need to be more cautious.
 
4. Low Blood Sugar (Hypoglycemia):
  • ○ This is more likely to occur if Retatrutide is used in combination with other diabetes medications that lower blood sugar, such as insulin or sulfonylureas.
  • ○ Symptoms: Shaking, sweating, dizziness, and confusion are signs of low blood sugar.
 
5. Allergic Reactions:
  • ○ Symptoms: Rash, itching, swelling, or difficulty breathing could indicate an allergic reaction. In severe cases, this could lead to anaphylaxis (a life-threatening reaction), though this is rare.
 
6. Gallbladder Problems:
  • ○ Gallstones: There is a potential risk of developing gallstones, which could lead to pain in the upper abdomen, nausea, and vomiting.
Q: How should I use VLS Retatrutide?
Use VLS Retatrutide exactly as your healthcare provider tells you to.
  • • VLS Retatrutide is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm. Do not inject VLS Retatrutide into a muscle (intramuscularly) or vein (intravenously).
  • • Use VLS Retatrutide 1 time each week, on the same day each week, at any time of the day.
  • • You may change the day of the week you use VLS Retatrutide as long as your last dose was given 2 or more days before.
  • • If you miss a dose of VLS Retatrutide, take the missed dose as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and take your next dose on the regularly scheduled day.
  • • VLS Retatrutide may be taken with or without food.
  • • Do not mix insulin and VLS Retatrutide together in the same injection.
  • • You may give an injection of VLS Retatrutide and insulin in the same body area (such as your stomach area), but not right next to each other.
  • • Change (rotate) your injection site with each injection. Do not use the same site for each injection.
  • • Check your blood sugar as your healthcare provider tells you to.
  • • Stay on your prescribed diet and exercise program while using VLS Retatrutide.
  • • Talk to your healthcare provider about how to prevent, recognize and manage low blood sugar(hypoglycemia), high blood sugar (hyperglycemia), and problems you have because of your diabetes.
  • • Your healthcare provider will check your diabetes with regular blood tests, including your blood sugar levels and your hemoglobin A1C.
  • • Do not share your VLS Retatrutide pen with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
  • • Your dose of VLS Retatrutide and other diabetes medicines may need to change because of change in level of physical activity or exercise, weight gain or loss, increased stress, illness, change in diet, fever, trauma, infection, surgery or because of other medicines you take.
  • • If you take too much VLS Retatrutide, call your healthcare provider or go to the nearest hospital emergency room right away.
Q: When should I not use VLS Retatrutide?
Do not use VLS Retatrutide if:
  • • Risk of Thyroid Tumors: Like other GLP-1 receptor agonists, retatrutide could increase the risk of developing thyroid tumors, including medullary thyroid cancer. People with a family history of MTC or MEN 2 are generally advised not to use drugs in this class.
  • • Gastrointestinal Side Effects: Retatrutide, like other similar medications, may cause gastrointestinal side effects such as nausea, vomiting, diarrhea, or constipation. Those with severe gastrointestinal conditions (e.g., gastroparesis, bowel obstruction) might experience worsened symptoms or complications.
  • • Risk of Hypoglycemia: While retatrutide has shown potential for controlling blood sugar in Type 2 diabetes, it is not intended for use in Type 1 diabetes. The medication may cause blood sugar to drop too low in people with Type 1 diabetes, potentially leading to dangerous hypoglycemic episodes.

Related products

Home
Account
1
Search
Scroll to Top